6 results about "Peptic ulcer" patented technology

Administration of pentadecanoylcarnitine or pentadecanoic acid is provided for prevention, management or treatment of aggression, allergies, allergic rhinitis, Alzheimer's disease, anxiety and anxiety disorders, amyotrophic lateral sclerosis, arthritis, asthma, atherosclerosis, attention-deficit hyperactivity disorder, bipoloar disorder, brain damage, cancer, cardiovascular disease, cholestatic pruritis, depression, chronic obstructive pulmonary disease (COPD), cocaine abuse, cough, dermatitis, depression, drug-seeking behavior, gastrointestinal disorders, facial erythema associated with rosacea, glaucoma, hepatic diseases, hyperactive bladder, hypersensitivity disorders, hypertension, impulsivity, inflammation, mental disorders and conditions, metabolic disorders, migraines, nasal and sinus congestion, nausea, neuropathic pain with and symptoms of multiple sclerosis, neurological and neuropsychiatric disorders, obesity, obsessive-compulsive disorders, opioid-induced respiratory depression, osteoarthritis, pain, Parkinson disease, pathological gambling, peptic ulcers, schizophrenia, sleep disorders, spinal cord injury, tardive dyskinesia, tics and behavioral problems with Tourette's syndrome; as well as for supporting appetite, cardiovascular health, hematologic health, memory, metabolic health, mood, prolonged REM sleep, renal health, sexuality, sociability and metabolic, hematological, renal, and weight loss.

The invention relates to a natural pharmaceutical composition for prevention and treatment of gastric ulcer and a preparation method of the natural pharmaceutical composition. The natural pharmaceutical composition comprises active natural medicinal ingredients. It is composed of turpentine oil, black seed oil, vitamin D and hyaluronic acid. The natural pharmaceutical composition provides a significant synergistic effect, combining anti-inflammatory, antibacterial, and gastroprotective properties, while also ensuring cost-effectiveness and minimal side effects compared to conventional treatments. Beside gastric ulcer is effective in relief of symptoms associated with gastric ulcer. The natural composition has the advantages of accurate curative effects, preparation stability, simplicity and feasibility in process and suitableness for industrial production.

The invention belongs to the technical field of biological medicines, and particularly relates to an imidazo [1, 2-a] pyridine compound as well as a preparation method and application thereof. The structural formula of the imidazo [1, 2-a] pyridine compound is shown in the specification, and R is selected from sodium ions, potassium ions, calcium ions, magnesium ions, lithium ions or ammonium ions; when R is a sodium ion, a potassium ion, an ammonium ion or a lithium ion, n = 2; and when R is a calcium ion or a magnesium ion, n = 1. The imidazo [1, 2-a] pyridine compound provided by the invention shows high solubility, high dissolution rate and excellent biological activity for inhibiting gastric acid secretion, and provides a new choice for treating gastric acid related diseases such as peptic ulcer.

The present application discloses polymorphs of asiaticoside, a preparation method and medical use thereof. The present application firstly proves that asiaticoside has polymorphism, and provides various crystal forms of asiaticoside suitable for being used as a raw material, which can be used for developing asiaticoside preparations with controllable quality. The present application provides a simple, easy and environment-friendly preparation method of the polymorphs of asiaticoside, which is suitable for large-scale production. The polymorphs of asiaticoside or pharmaceutical compositions containing the crystal forms of asiaticoside can be used for preventing and treating diseases including type I interferon disease, peptic ulcer, Parkinson's disease, ulcerative colitis, systemic sclerosis, liver fibrosis, pulmonary fibrosis, renal fibrosis, Alzheimer's disease, depression, diabetic foot ulcer and refractory wound.

The invention relates to a pharmaceutical composition for preventing or treating peptic ulcer. The pharmaceutical composition comprises a compound shown in a formula I or pharmaceutically acceptable salt and a non-steroidal anti-inflammatory drug.

This invention belongs to the field of biomedical technology, specifically relating to an imidazo[1,2-a]pyridine compound, its preparation method, and its applications. The imidazo[1,2-a]pyridine compound has the following structural formula: [Formula omitted for brevity]. Wherein, R is selected from sodium ions, potassium ions, calcium ions, magnesium ions, lithium ions, or ammonium ions; when R is a sodium ion, potassium ion, ammonium ion, or lithium ion, n=2; when R is a calcium ion or magnesium ion, n=1. The imidazo[1,2-a]pyridine compound provided by this invention exhibits high solubility, high dissolution rate, and excellent bioactivity in inhibiting gastric acid secretion, providing a new option for treating gastric acid-related diseases such as peptic ulcers.